GLP-1 Refund

GLP-1 Refund

GLP-1 injury information

Request Review

GLP-1 Mental Health Questions

Reviewed April 2026

GLP-1 medications and mental-health questions after the 2026 FDA label change

This topic changed materially in 2026. On January 13, 2026, FDA requested removal of suicidal-behavior and ideation warning language from obesity GLP-1 labels after a review found no increased risk. If someone has suicidal thoughts, self-harm risk, or an immediate mental-health crisis, emergency or crisis support comes first.

Request ReviewReview Sources

At A Glance

FDA requested removal of suicidality warning language from obesity GLP-1 labels on January 13, 2026 after a review found no increased risk.
That does not make an individual report unimportant, but it does change how carefully this topic should be discussed.
Urgent mental-health symptoms still require immediate clinical or crisis support, not a website form.
This information should not be read as proof of legal causation in any individual situation.

What changed in 2026

On January 13, 2026, FDA requested removal of suicidal-behavior and ideation warning language from the GLP-1 obesity labels that still carried it. The agency said its comprehensive review did not find an increased risk.

Older articles and screenshots can be out of date on this topic because the FDA position changed in January 2026.

References For This Section

FDA: removal of suicidal-behavior and ideation warning from GLP-1 RA obesity labelsFDA label: Wegovy (semaglutide)

Why safety comes first

Mental-health symptoms are medically and personally serious. Immediate safety, crisis support, and clinician review come before any question about documentation or claims.

Even though the current FDA position is different from older label language, anyone dealing with suicidal thoughts, self-harm risk, or a mental-health crisis should treat the situation as urgent and seek help immediately.

References For This Section

FDA: removal of suicidal-behavior and ideation warning from GLP-1 RA obesity labels

What to document after safety is addressed

If the immediate safety issue has been addressed, write down the medication, dose changes, when symptoms started, whether there was a prior mental-health history, whether a clinician recommended stopping the medication, and what treatment or follow-up occurred.

That does not determine legal causation by itself. It simply creates a usable record for clinicians and, if needed later, for a careful discussion of what happened under the current regulatory picture.

References For This Section

FDA: removal of suicidal-behavior and ideation warning from GLP-1 RA obesity labels

When To Seek Medical Care

  • If there are suicidal thoughts, self-harm risk, or an immediate mental-health crisis, seek emergency or crisis help right away rather than using a website form.
  • New or worsening depression should be brought to a licensed clinician promptly.
  • Address immediate safety first, then document the timeline if it is still relevant later.

FAQ

Does this topic establish causation by itself?+

No. It explains the current FDA position and the right safety-first response, but it does not prove causation in any individual situation.

Why include this topic on the site at all if FDA removed the warning language?+

Because the topic still comes up, older content is often out of date, and the current FDA action is important context.

Official References

The references below are the main public sources used for this page, usually current labeling plus agency or NIH material on symptoms, evaluation, or record access.